Biomarker for myasthenia gravis
AssigneeHeinrich-Heine-Universitaet Duesseldorf
InventorsSven Guenther MEUTH, Tobias RUCK, Christopher Jannik NELKE, Christina Barbara SCHROETER
Life of this patent
Estimating the term…
Abstract
The present invention relates to a method for determining disease activity of myasthenia gravis in a patient, comprising determining the inter-alpha-trypsin inhibitor heavy chain H3 (ITIH3) level in an in vitro sample from the patient. Furthermore, the invention relates to a kit for use in such method comprising means for determining the ITIH3 level in a sample and instructions for carrying out the method.
Claims21
1-15. (canceled)
A method for determining disease activity of myasthenia gravis in a patient, comprising determining the inter-alpha-trypsin inhibitor heavy chain H3 (ITIH3) level in an in vitro sample from the patient.
Use of ITIH3 as a biomarker for determining disease activity of myasthenia gravis in a patient.
Dependencies are inferred from the claim text.